- Home
- SUZ vs PCVX Comparison
SUZ vs PCVX Comparison
Compare SUZ & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SUZ | PCVX |
|---|---|---|
| Founded | 1924 | 2013 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 7.0B |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SUZ | PCVX |
|---|---|---|
| Price | $8.29 | $56.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $12.56 | ★ $109.00 |
| AVG Volume (30 Days) | ★ 2.3M | 1.2M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.30 | N/A |
| Revenue Next Year | $14.21 | N/A |
| P/E Ratio | $5.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.56 | $39.87 |
| 52 Week High | $11.54 | $65.00 |
Technical Indicators
Market Signals| Indicator | SUZ | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 37.71 | 44.39 |
| Support Level | $8.01 | $52.18 |
| Resistance Level | $8.61 | $58.77 |
| Average True Range (ATR) | 0.18 | 2.19 |
| MACD | -0.12 | -0.27 |
| Stochastic Oscillator | 1.30 | 30.24 |
Price Performance
Historical ComparisonAbout SUZ Suzano S.A.
Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.